Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $153

斯迪富維持Glaukos(GKOS.US)買入評級，上調目標價至153美元

moomoo資訊 · 12/02 20:31 · 評級/大行評級

Stifel analyst Thomas Stephan maintains $Glaukos (GKOS.US)$ with a buy rating, and adjusts the target price from $145 to $153.

According to TipRanks data, the analyst has a success rate of 46.7% and a total average return of 10.8% over the past year.

AnalystRecentRatingAutoNews_211107_20241202_12eeb75d1481aa640459fc05618c25d4d0b1b531_1733218320888411_mm_en

Furthermore, according to the comprehensive report, the opinions of $Glaukos (GKOS.US)$'s main analysts recently are as follows:

iDose is recognized as an excellent product with significant long-term potential. However, the current valuation poses challenges in identifying further upside relative to other stocks. Additionally, while there are promising assets in development, their realization is expected to take some time.
Recent tracking indicates a resurgence in the number of new iDose-trained surgeons, bolstering confidence in surpassing the predicted $100M iDose sales by 2025. Continued advancements in Medicare Administrative Contractor reimbursements are also foreseen to significantly accelerate iDose revenue growth by mid-2025.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

斯迪富分析師Thomas Stephan維持$Glaukos (GKOS.US)$買入評級，並將目標價從145美元上調至153美元。

根據TipRanks數據顯示，該分析師近一年總勝率為46.7%，總平均回報率為10.8%。

AnalystRecentRatingAutoNews_211107_20241202_12eeb75d1481aa640459fc05618c25d4d0b1b531_1733218320888411_mm_tc

此外，綜合報道，$Glaukos (GKOS.US)$近期主要分析師觀點如下：

iDose被公認爲具有巨大長期潛力的優秀產品。但是，當前的估值在確定相對於其他股票的進一步上行空間方面構成了挑戰。此外，儘管有前景的資產正在開發中，但其實現預計需要一些時間。
最近的追蹤表明，接受過iDose培訓的新外科醫生人數有所回升，這增強了人們對到2025年超過預期的1億美元iDose銷售額的信心。預計到2025年中期，醫療保險管理承包商報銷的持續進展將顯著加速iDose收入的增長。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $153

Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $153

風險及免責聲明

聲明